7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

Please reload

Featured Posts

MaxCyte is a Featured Speaker at 2nd International Stem Cells and Regenerative Medicine 2007

January 15, 2007


Engineering Cells for Clinical Regenerative Applications: A Practical Approach


Gaithersburg, Maryland -– MaxCyte Inc., a clinical stage therapeutic company and pioneer in non-viral cell loading systems, announces Joseph Fratantoni, M.D. will be a featured speaker at the 2nd International Stem Cells and Regenerative Medicine 2007 meeting on January 22 - 24, 2007 in San Francisco, CA.


Dr. Fratantoni's presentation entitled "Engineering Cells for Clinical Regenerative Applications: A Practical Approach to a Fundamental Problem in Translational Research" will provide an overview of the need to engineer stem cells, a brief discussion of the regulatory hurdles with existing cell engineering techniques and discuss the company's enabling technology for engineering stem cells.


About MaxCyte


MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.


Joseph Fratantoni, MD, Dr. Joseph Fratantoni serves as Vice President of Clinical Development and Medical Affairs and is MaxCyte's Chief Medical Officer. Dr. Fratantoni has extensive experience in hematology and transfusion medicine, including eight years at NIH, 18 years at FDA and, most recently, three years at the Maryland consulting firm C.L. McIntosh and Associates where he was Vice President, Biologics. At FDA, Dr. Fratantoni was the Director of the Division of Hematology at the Center for Biologics Evaluation and Research (CBER) where his areas of responsibility included research and review of cellular blood components for transfusion, plasma derivatives, cell separators, coagulation products and blood substitutes, and a number of blood-related biotechnology products and issues. His research contributions included new approaches to laboratory evaluation of platelets and studies on viral inactivation of cellular components. Dr. Fratantoni has maintained an involvement in medical teaching and patient care throughout his career and holds an appointment as Clinical Professor of Medicine at the Uniformed Services University. He earned an M.D. from Cornell University Medical College, an A.M. in chemistry from Harvard University, and a B.S. in chemistry from Fordham College.


For more information, visit http://www.maxcyte.com/


Please reload